First Trust Advisors LP Buys 189,245 Shares of Krystal Biotech, Inc. $KRYS

First Trust Advisors LP lifted its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 571.3% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 222,370 shares of the company’s stock after acquiring an additional 189,245 shares during the quarter. First Trust Advisors LP owned approximately 0.77% of Krystal Biotech worth $30,567,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Main Management ETF Advisors LLC lifted its holdings in Krystal Biotech by 1.7% during the second quarter. Main Management ETF Advisors LLC now owns 5,131 shares of the company’s stock valued at $705,000 after purchasing an additional 84 shares in the last quarter. M&T Bank Corp lifted its stake in shares of Krystal Biotech by 2.3% during the 2nd quarter. M&T Bank Corp now owns 3,785 shares of the company’s stock valued at $520,000 after buying an additional 85 shares in the last quarter. Brooklyn Investment Group boosted its holdings in Krystal Biotech by 291.7% in the 1st quarter. Brooklyn Investment Group now owns 141 shares of the company’s stock worth $25,000 after buying an additional 105 shares during the period. CWM LLC boosted its holdings in Krystal Biotech by 7.2% in the 2nd quarter. CWM LLC now owns 1,583 shares of the company’s stock worth $218,000 after buying an additional 107 shares during the period. Finally, Maryland State Retirement & Pension System increased its stake in Krystal Biotech by 1.7% in the 2nd quarter. Maryland State Retirement & Pension System now owns 7,474 shares of the company’s stock worth $1,027,000 after buying an additional 123 shares in the last quarter. Institutional investors own 86.29% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on KRYS. Weiss Ratings restated a “hold (c+)” rating on shares of Krystal Biotech in a research report on Monday. Bank of America boosted their price target on Krystal Biotech from $182.00 to $255.00 and gave the stock a “buy” rating in a report on Friday, October 17th. Citigroup increased their price objective on shares of Krystal Biotech from $166.00 to $198.00 and gave the company a “neutral” rating in a report on Tuesday, November 4th. Guggenheim set a $224.00 price objective on shares of Krystal Biotech and gave the company a “buy” rating in a research report on Friday, October 17th. Finally, Chardan Capital upped their target price on shares of Krystal Biotech from $216.00 to $220.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. Six analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $228.14.

Insider Activity at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $220.16, for a total transaction of $5,504,000.00. Following the completion of the sale, the insider owned 1,413,711 shares of the company’s stock, valued at approximately $311,242,613.76. The trade was a 1.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 13.70% of the company’s stock.

Krystal Biotech Trading Up 2.2%

KRYS stock opened at $239.72 on Thursday. Krystal Biotech, Inc. has a 12 month low of $122.80 and a 12 month high of $241.85. The stock has a market cap of $6.95 billion, a PE ratio of 35.94 and a beta of 0.48. The company has a 50-day moving average price of $201.43 and a 200 day moving average price of $165.04.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, November 3rd. The company reported $2.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.12 by $1.54. Krystal Biotech had a return on equity of 19.36% and a net margin of 53.30%.The firm had revenue of $97.80 million during the quarter, compared to analyst estimates of $93.72 million. Sell-side analysts forecast that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).